PTHS
Pelthos Therapeutics Inc.
$27.50
-4.25%
$95.6M
No data for this timeframe.
Vol
Market Cap$95.6M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (92%)
Inst. Holders3 funds
Inst. Value$2.2M
Insider Activity0B / 5S
Insider Net $-$69.8K
SEC Reports6
Press Releases2
Exchange NYSE·Sector Biological Products, (No Diagnostic Substances)·Inc. NV·CIK 0001919246·Prev Close $28.72
Recent Activity
May 28, 2026
SEC
Pelthos Therapeutics filed an 8-K announcing that CEO Scott Plesha will present and hold one-on-one investor meetings at
8-K — Impact 3/10
May 28, 2026
other
Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
<p align="justify">DURHAM, N.C., May 28, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE
May 22, 2026
SEC
Francis Knuettel II, an officer of Pelthos Therapeutics Inc. (PTHS), filed a Form 144 on 5/22/2026 indicating intent to
144 — Impact 2/10
May 22, 2026
Insider
Francis Knuettel II sold 1,500 shares
CFO, Treas & Secty @ $26.84 ($40.3K)
May 22, 2026
Insider
Francis Knuettel II disposed of 13,947 shares
CFO, Treas & Secty
May 22, 2026
Insider
Francis Knuettel II was granted 59,500 shares
CFO, Treas & Secty
May 21, 2026
SEC
Pelthos Therapeutics filed an 8-K reporting two significant events: (1) the dismissal of auditor CBIZ CPAs P.C. and enga
8-K — Impact 6/10
Mar 31, 2026
Press
Pelthos Therapeutics announced the first patient dosed in a Phase 1b/2a trial for CT2000, a novel eye drop targeting NaV
Impact 5/10
Price Targets
$57.71
+109.9% upside
Strong Buy
Current $27.50
Low $48.00
Median $55.00
High $75.00
7 analysts
$48.00
$75.00
Analyst Ratings
3Strong Buy
9Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 15, 2026 | Oppenheimer | MAINTAIN | Outperform → Outperform |
| Apr 1, 2026 | Cantor Fitzgerald | INITIATE | Overweight |
| Mar 20, 2026 | Oppenheimer | MAINTAIN | Outperform → Outperform |
| Mar 19, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Feb 27, 2026 | Piper Sandler | INITIATE | Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-2.95 ▼ -17.4% | $-4.19 — $-1.54 | 45% YoY | 4 |
| Next Q | $-1.89 ▼ -29.2% | $-3.27 — $-0.69 | 64% YoY | 4 |
| Current FY | $-10.66 ▲ +2.7% | $-16.43 — $-6.88 | 20% YoY | 4 |
| Next FY | $-2.13 ▼ -1923.8% | $-5.09 — $1.50 | 80% YoY | 4 |
Latest Reports
NEUTRAL
8-K
3/10
Pelthos Therapeutics filed an 8-K announcing that CEO Scott Plesha will present and hold one-on-one investor meetings at
May 28, 2026
NEUTRAL
144
2/10
Francis Knuettel II, an officer of Pelthos Therapeutics Inc. (PTHS), filed a Form 144 on 5/22/2026 indicating intent to
May 22, 2026
NEUTRAL
Press
5/10
Pelthos Therapeutics announced the first patient dosed in a Phase 1b/2a trial for CT2000, a novel eye drop targeting NaV
Mar 31, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $2.0M | — |
| VANGUARD FIDUCIARY TRUST CO | $206.3K | — |
| CITIGROUP INC | $21.00 | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 22, 2026 | Francis Knuettel | SELL | $40.3K |
| May 22, 2026 | Francis Knuettel | D | $0.00 |
| May 22, 2026 | Francis Knuettel | A | $0.00 |
| May 22, 2026 | Francis Knuettel | D | $0.00 |
| May 14, 2026 | Friedberg Ezra | F | $3.9K |
3 institutional holders with $2.2M total value (102,911 shares) as of 2026-Q1. Top holders: VANGUARD, VANGUARD, CITIGROUP.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 93,093 | $2.0M | 90.5% | — |
| 2 | VANGUARD FIDUCIARY TRUST CO | 9,817 | $206.3K | 9.5% | — |
| 3 | CITIGROUP INC | 1 | $21.00 | 0.0% | — |
9 unique insiders with 24 transactions. Net insider value: -$69.8K ($0.00 bought, $69.8K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 22, 2026 | Francis Knuettel II | CFO, Treas & Secty | SELL | 1,500 | $26.84 | $40.3K |
| May 22, 2026 | Francis Knuettel II | CFO, Treas & Secty | D | 13,947 | — | — |
| May 22, 2026 | Francis Knuettel II | CFO, Treas & Secty | AWARD | 59,500 | — | — |
| May 22, 2026 | Francis Knuettel II | CFO, Treas & Secty | D | 42,500 | — | — |
| May 14, 2026 | Friedberg Ezra M | Director | TAX W/H | 144 | $27.01 | $3.9K |
| Apr 2, 2026 | Friedberg Ezra M | Director | SELL | 293 | $20.51 | $6.0K |
| Apr 2, 2026 | Pauls Matthew | Director | SELL | 415 | $20.52 | $8.5K |
| Apr 2, 2026 | Greenleaf Peter | Director | SELL | 420 | $20.52 | $8.6K |
| Apr 2, 2026 | Malamut Richard | Director | SELL | 310 | $20.51 | $6.4K |
| Nov 13, 2025 | Malamut Richard | Director | AWARD | 2,454 | — | — |
| Jul 2, 2025 | Francis Knuettel II | CFO, Treas & Secty | AWARD | 33,472 | — | — |
| Jul 2, 2025 | Baxter Richard B | Director | AWARD | 19,108 | — | — |
| Jul 2, 2025 | Rangarao Sai | Chief Commercial Officer | AWARD | 30,518 | — | — |
| Jul 2, 2025 | Pauls Matthew | Director | AWARD | 25,478 | — | — |
| Jul 2, 2025 | Greenleaf Peter | Director | AWARD | 25,478 | — | — |
| Jul 2, 2025 | Plesha Scott M. | CEO and President | AWARD | 83,678 | — | — |
| Jul 2, 2025 | Malamut Richard | Director | AWARD | 19,108 | — | — |
| Jul 2, 2025 | Davis Todd C | Director | AWARD | 19,108 | — | — |
| Jul 2, 2025 | Friedberg Ezra M | Director | AWARD | 19,108 | — | — |
| Nov 13, 2024 | Davis Todd C | Director | AWARD | 4,961 | — | — |
| Nov 13, 2024 | Friedberg Ezra M | Director | AWARD | 2,454 | — | — |
| Jun 14, 2024 | Malamut Richard | Director | AWARD | 6,450 | — | — |
| Jun 14, 2024 | Davis Todd C | Director | AWARD | 12,900 | — | — |
| Jun 14, 2024 | Friedberg Ezra M | Director | AWARD | 6,450 | — | — |
6 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 5 neutral. Avg impact: 4.0/10.
NEUTRAL
8-K
3/10
Pelthos Therapeutics filed an 8-K announcing that CEO Scott Plesha will present and hold one-on-one
May 28, 2026
NEUTRAL
144
2/10
Francis Knuettel II, an officer of Pelthos Therapeutics Inc. (PTHS), filed a Form 144 on 5/22/2026 i
May 22, 2026
BEARISH
8-K
6/10
Pelthos Therapeutics filed an 8-K reporting two significant events: (1) the dismissal of auditor CBI
May 21, 2026
NEUTRAL
8-K
5/10
Pelthos Therapeutics reported Q1 2026 revenue of $10.9M (product revenue $10.7M, up 17% QoQ from $9.
May 14, 2026
NEUTRAL
PRESS-RELEASE
5/10
Pelthos Therapeutics reported Q1 2026 EPS of -$3.09, beating the -$3.58 consensus by 13.7%, on total
May 14, 2026
NEUTRAL
3
3/10
John M. Gay, Chief Financial Officer of Pelthos Therapeutics Inc., filed a Form 3 disclosing initial
Apr 20, 2026
Current analyst consensus: Strong Buy (92% buy). Based on 13 analysts: 3 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$57.71 mean target
+109.9% upside
Strong Buy (1.14)
$48.00 Low
$75.00 High
| Metric | Value |
|---|---|
| Current Price | $27.50 |
| Target Low | $48.00 |
| Target Mean | $57.71 |
| Target Median | $55.00 |
| Target High | $75.00 |
| # Analysts | 7 |
| Recommendation | Strong Buy (1.14) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-2.95 | $-4.19 | $-1.54 | 45.2% | -17.4% | 0↑ 1↓ | $0.0B | — | 4 |
| Next Q 2026-09-30 |
$-1.89 | $-3.27 | $-0.69 | 64.3% | -29.2% | 0↑ 1↓ | $0.0B | 149.3% | 4 |
| Current FY 2026-12-31 |
$-10.66 | $-16.43 | $-6.88 | 19.8% | +2.7% | — | $0.1B | 280.0% | 4 |
| Next FY 2027-12-31 |
$-2.13 | $-5.09 | $1.50 | 80.1% | -1923.8% | 0↑ 2↓ | $0.1B | 89.9% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-2.947 | |
| 7d ago | $-2.947 | |
| 30d ago | $-2.510 | -0.438 |
| 60d ago | $-2.510 | -0.438 |
| 90d ago | $-2.450 | -0.497 |
5 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 15, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Apr 1, 2026 | Cantor Fitzgerald | INITIATE | — | Overweight |
| Mar 20, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Mar 19, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 27, 2026 | Piper Sandler | INITIATE | — | Overweight |
| Feb 26, 2026 | Roth Capital | MAINTAIN | Buy | Buy |
| Jan 26, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 9 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 3 | 9 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| Jan 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 28, 2026
other
Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
<p align="justify">DURHAM, N.C., May 28, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company commi
May 14, 2026
earnings
Pelthos Therapeutics Announces First Quarter 2026 Financial Results
<p align="center"><em> ZELSUVMI</em><sup>®</sup> <em>net product revenue grew 17% quarter over quarter from $9.1 million in the fourth quarter of 2025
May 14, 2026
earnings_calendar
PTHS Q1 2026 Earnings Scheduled — 2026-05-14
May 1, 2026
earnings
Pelthos Therapeutics to Report First Quarter 2026 Financial Results on May 14, 2026
Company to hold a conference call at 8:30 a.m. ET <pre>Company to hold a conference call at 8:30 a.m. ET</pre>
Apr 14, 2026
other
Pelthos Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium
<p align="justify">DURHAM, N.C., April 14, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company com
Apr 10, 2026
leadership
Pelthos Therapeutics Announces CFO Transition
Senior Vice President, Finance & Accounting John M. Gay named Chief Financial Officer <pre>Senior Vice President, Finance & Accounting John M. Gay nam
Mar 31, 2026
fda
Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain
<p align="center"><em>First clinical trial conducted in human subjects to evaluate CT2000 for the treatment of both acute ocular pain and chronic ocul
Mar 19, 2026
earnings
Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results
<p align="center"><em>ZELSUVMI</em><em>™</em><em> net product revenue grew 28% Quarter over Quarter to $9.1 million, bringing total ZELSUVMI net produ
Mar 19, 2026
earnings_calendar
PTHS Q4 2025 Earnings Scheduled — 2026-03-19
Mar 12, 2026
other
Pelthos Therapeutics to Present at 38th Annual ROTH Conference
<p align="justify">DURHAM, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company com
Mar 9, 2026
earnings
Pelthos Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
Company to hold a conference call at 8:00 a.m. ET <pre>Company to hold a conference call at 8:00 a.m. ET</pre>